<DOC>
	<DOCNO>NCT00278408</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some find cancer cell kill carry cancer-killing substance . Others interfere ability cancer cell grow spread . Drugs use chemotherapy , cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone , work different way stop growth cancer cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill cancer cell . Giving rituximab combination chemotherapy together radiation therapy may kill cancer cell . It yet know schedule rituximab combination chemotherapy effective give without radiation therapy treat non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study two different schedule rituximab combination chemotherapy without radiation therapy compare well work treat patient aggressive B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy With Without Radiation Therapy Treating Patients With B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare time treatment failure patient previously untreated , low-risk , aggressive , B-cell non-Hodgkin 's lymphoma treat 2 different schedule immunochemotherapy comprise rituximab , cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone v without radiotherapy . Secondary - Compare time progression patient treat regimen . - Compare overall disease-free/relapse-free survival patient treat regimen . - Compare complete response rate patient treat regimen . - Compare tumor control patient treat regimen . - Compare safety regimens patient . - Compare pharmacoeconomics regimen . - Compare patient adherence regimen . OUTLINE : This open-label , randomize , multicenter study . Patients stratify accord study center , serum lactic dehydrogenase level ( ≤ upper limit normal [ ULN ] v &gt; ULN ) , disease stage ( I II v III IV ) , ECOG performance status ( 0-1 v 2-3 ) , bulky disease , extranodal involvement . Patients initial bulky disease and/or qualify extranodal involvement randomize 1 4 treatment arm . Patients non-bulky disease randomize treatment arm I III . All patient give option receive 1-week course pretreatment therapy comprise vincristine IV day -6 oral prednisone daily day -6 0 . - Arm I ( R-CHOP-21 ) : Patients receive R-CHOP immunochemotherapy comprise rituximab IV , cyclophosphamide IV 15 minute , doxorubicin IV , vincristine IV day 1 oral prednisone daily day 1-5 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . - Arm II ( R-CHOP-21 radiotherapy ) : Patients receive R-CHOP arm I . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Beginning 2-6 week last course R-CHOP , patient achieve complete remission ( CR ) undergo radiotherapy 5 day week approximately 5½ week . - Arm III ( R-CHOP-14 ) : Patients receive R-CHOP arm I . Patients also receive filgrastim ( G-CSF ) subcutaneously daily day 4-13 blood count recover . Treatment repeat every 14 day 6 course absence disease progression unacceptable toxicity . - Arm IV ( R-CHOP-14 radiotherapy ) : Patients receive R-CHOP arm I . Patients also receive G-CSF arm III . Treatment repeat every 14 day 6 course absence disease progression unacceptable toxicity . Beginning 2-6 week last course R-CHOP , patient achieve CR undergo radiotherapy arm II . Patients arm undergo restaging disease course 3 6 R-CHOP . Patients stable disease 6 course disease progression course 3 6 proceed salvage chemotherapy study . Patients achieve partial remission unconfirmed CR 6 course undergo additional restaging 4 week later . Patients disease progression proceed salvage chemotherapy study . Patients achieve CR 6 course R-CHOP confirm CR additional restaging undergo radiotherapy accord randomization ( ) . After completion study treatment , patient follow periodically 5 year annually thereafter . PROJECTED ACCRUAL : A total 1,072 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive Bcell nonHodgkin 's lymphoma , include follow subtypes : Grade 3 follicular lymphoma Diffuse Bcell lymphoma , include diffuse large cell lymphoma follow variant : Centroblastic Immunoblastic Plasmablastic Anaplastic large cell Tcellrich Bcell lymphoma Primary effusion lymphoma Intravascular Bcell lymphoma Primary mediastinal Bcell lymphoma Burkitt 's Burkittlike lymphoma Mantle cell lymphoma ( blastoid ) Aggressive marginal zone lymphoma ( monocytoid ) Previously untreated disease CD20positive disease International prognostic index ( IPI ) score 0 1 ( ageadjusted ) Only patient bulky disease , define large single conglomerate tumor ≥ 7.5 cm diameter , allow IPI score 0 No mucosaassociated lymphoid tissue ( MALT ) lymphoma No CNS involvement lymphoma ( intracerebral , meningeal , intraspinal ) PATIENT CHARACTERISTICS : ECOG performance status 02 Platelet count ≥ 100,000/mm³ WBC ≥ 2,500/mm³ No know hypersensitivity study medication No know HIVpositivity No active hepatitis infection Not pregnant lactate Negative pregnancy test No malignancy within past 5 year except carcinoma situ basal cell skin cancer No impair leave ventricular function No severe cardiac arrhythmia No impair organ function No serious disorder PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy No prior immunosuppressive treatment cytostatics No concurrent participation treatment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
</DOC>